Re: [NMusers] ASCO and pharmacometrics

From: Naoto Hayashi <neohayashi_at_gmail.com>
Date: Wed, 6 Apr 2016 16:46:10 +0900

Dear Joachim,

Thank you so much for your reply.

Their abstract instruction allows very small number of characters, and no
enough room to express what we had established in this work.

Although we described the unique results in the table, they probably could
not understand its meaning, or the model's outcome that I was so excited
has no meaning to oncologist.

It seemed so nice work for me and I hope that US pharmacometrician society
would communicate with ASCO people for our future.

Thanks!

Best regards,
Naoto Hayashi, PhD


2016-04-06 15:58 GMT+09:00 Joachim Grevel <jgrevel_at_btconnect.com>:

> Dear Naoto,
>
> Your experience is also mine. For a combined TTE safety and efficacy
> analysis I earned the online publication. The organisers do not believe i=
n
> modelling, unless it describes what is already visible in graphs and tabl=
es
> of raw data.
>
> This is just my personal impression. I have not been to ASCO either.
>
>
>
> Good luck,
>
> Joachim
>
>
>
>
>
> *Joachim Grevel, PhD*
>
> Scientific Director
>
> BAST Inc Limited
>
> Science & Enterprise Park
>
> Loughborough University
>
> Loughborough, LE11 3AQ
>
> United Kingdom
>
>
>
> Tel: +44 (0)1509 222908
>
> www.bastinc.eu
>
>
>
>
>
>
>
> *From:* owner-nmusers_at_globomaxnm.com [mailto:owner-nmusers_at_globomaxnm.com=
]
> *On Behalf Of *Naoto Hayashi
> *Sent:* 06 April 2016 02:38
> *To:* nmusers_at_globomaxnm.com
> *Subject:* [NMusers] ASCO and pharmacometrics
>
>
>
>
>
> Dear all,
>
>
>
> I have a question and appreciate it if somebody can answer to me.
>
>
>
> We had submitted an abstract to ASCO annual meeting presentation 2016, an=
d
> its contents included a pharmacometrics work of quantitative safety profi=
le
> analysis of an anticancer drug. The behave of the safety index time
> courses is very unique and its results showed a very high usefulness of
> this drug. The abstract also included the table of population PK/PD
> parameters that expressed its nature, and it was compared with the simila=
r
> older drug safety profile and demonstrated very high safer profile
> quantitatively.
>
>
>
> I have some experiences to publish some articles of population PK/PD work
> in several clinical pharmacology journals in the past, and I was so
> confident for just a poster presentation in ASCO. However, the judgment
> was “publication only”, i.e. just presentation in online =
but no poster
> presentation and no official record of publication officially.
>
>
>
> So, my question is whether pharmacometrics work is difficult to be picked
> up in ASCO presentation. Or, was my work evaluated to have no worth to b=
e
> presented even in poster session because the pharmacometrics works
> presented in ASCO are having very high level?
>
>
>
> I have never visited ASCO before, and I just want to hear opinions about
> how much of importance is considered for pharmacometrics work in ASCO.
>
>
>
> Thanks a lot in advance for your comments/thoughts.
>
>
>
> Best regards,
>
> Naoto Hayashi
>

Received on Wed Apr 06 2016 - 03:46:10 EDT

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:49:45 EDT